Copyright 2016 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
The FDA has approved atezolizumab to treat urothelial carcinoma, the most common type of bladder cancer. Marketed as Tecentriq, the drug is the first PD-1/PD-L1 inhibitor, a form of immunotherapy, approved to treat bladder cancer.
Atezolizumab’s safety and efficacy were studied in a single-group trial with 310 patients who had locally advanced or metastatic urothelial carcinoma. About 15% of the patients treated had at least partial shrinkage of their tumors lasting from 2 to 14 months. Among patients who had high levels of PD-L1 protein expression, 26% experienced some tumor shrinkage compared with 9.5% who had low levels of PD-L1 expressed (http://1.usa.gov/206G1Nc).
Voelker R. New Bladder Cancer Drug. JAMA. 2016;316(1):24. doi:10.1001/jama.2016.8071